An AI-native biotechnology company building next-generation human vaccines and proprietary AI training datasets — where biology, data, and artificial intelligence converge.
TeraVax Biotech addresses the compound uncertainty of biology, disease, and host–drug/vaccine interactions — the root cause of high costs and failure rates in drug and vaccine development. While many companies apply AI to noisy historical data, TeraVax Biotech generates its own high-quality, structured, prospectively designed datasets focused on human immunity.
With an initial emphasis on respiratory viruses and emerging zoonotic threats, the company's integrated biology–data–AI stack ensures every experimental cycle compounds the value of its strategic data assets.
In January 2026, GSK and Noetik entered into significant licenses and acquisitions of AI training datasets from third-party biotech companies — including upfront fees of $50 million plus milestones — validating the commercial demand for high-quality immunological training data.
Similar data licensing transactions completed over the past 3 years
Per deal in the GSK/Noetik benchmark transactions
Year of landmark AI training data deals signaling sector maturity
The ImmunAIsense platform is designed to generate high-quality training sets for both internal use and business development deals of this caliber.
Surging demand for high-quality, mechanistic immunological data to train next-generation AI disease models — a gap TeraVax Biotech is purpose-built to fill.
The global shift toward flexible, personalized vaccine platforms creates a premium market for modular, data-rich approaches like ImmunAIsense.
The increasing privatization of the healthcare knowledge stack rewards companies that own proprietary data-generating engines — not just data consumers.
By owning the data-generating engine and embedding it in a strategic UNC collaboration, TeraVax Biotech ensures its competitive advantage grows with every vaccine developed and every study run on ImmunAIsense.
TeraVax Biotech maximizes the value of its "biological operating system" through three complementary revenue streams — all strengthened by the UNC collaboration.
Developing high-value vaccine candidates for respiratory and emerging infections to reach clinical proof-of-concept, leveraging UNC expertise and clinical environments.
Offering ImmunAIsense as a platform for external vaccine programs under fee-for-service, co-development, or shared-IP models — while retaining platform-level model improvements.
Licensing AI-driven tools and datasets for antigen design, regimen selection, and biomarker-based performance prediction as high-margin digital products.
TeraVax Biotech holds an exclusive license for the T-Max and ImmunAIsense platforms in human health, anchored by US Patent 11,130,787 (issued 9/28/2021) — covering DNA and RNA compositions to treat or prevent viral diseases and cancer in humans, livestock, and companion animals.
TeraVax Biotech has assembled an elite Board of Directors, Academic Collaborators, and Advisory bodies. This multidisciplinary team provides the precise strategic oversight, scientific excellence, and market access required to accelerate the development and successful commercialization of our vaccine platform.
Our board brings decades of proven biopharmaceutical leadership, executive commercialization experience, and corporate governance to guide TeraVax from clinical stages to market launch.
Anchored by a powerful, multi-investigator strategic alliance with the University of North Carolina (UNC), our scientific team delivers the world-class immunology, AI modeling, and clinical framework necessary to validate and de-risk our pipeline.
TeraVax Biotech